Introduction
The type II topoisomerases, DNA gyrase and topoisomerase IV, show considerable amino acid sequence homology, yet the two enzymes have distinctive biological activities. Gyrase restores the negative supercoiled state of DNA during the replication and transcription processes, 1 whereas the decatenation activity of topoisomerase IV allows segregation of the daughter chromosomes during the last stages of the replication process. 2, 3 Both gyrase and topoisomerase IV are targets for the quinolones, 4 ,5 a class of synthetic antibiotics which exert their bactericidal effect by stabilizing the covalent topoisomerase-DNA reaction intermediate to form a ternary complex of DNA, topoisomerase and quinolone. 5 In Gram-negative bacteria such as Escherichia coli, fluoroquinolones preferentially target gyrase rather than topoisomerase IV, whereas in Gram-positive bacteria the target specificity is reversed. While acquisition of resistance is a single-step process in Staphylococcus aureus, 6, 7 in E. coli several steps are required. 8 The underlying mechanisms involve alterations in the genes gyrA/gyrB and parC/parE coding for subunits A and B of gyrase and topoisomerase IV, respectively, and mutations such as mar or norA affecting drug accumulation.
The spread of quinolone resistance increasingly limits the use of these agents. Novel approaches to overcome high-level resistance to currently available fluoroquinolones require that a new quinolone should have either equally high activity against both targets or significantly better activity against the primary target. With such an agent the probability of selecting resistant mutants should be lowered.
The new 8-methoxy-6-fluoroquinolone, moxifloxacin, has activity against Gram-negative bacteria similar to that of ciprofloxacin but superior potency against Grampositive bacteria including S. aureus and Streptococcus pneumoniae. 9 To evaluate the antibacterial potential of moxifloxacin for the treatment of infections caused by quinolone-resistant pathogens we determined the MICs of moxifloxacin in comparison with those of nine other fluoroquinolones for mutants of E. coli and S. aureus. The inhibitory activities of moxifloxacin and five other fluoroquinolones were determined against isolated E. coli type II
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Materials and methods

Quinolone antibacterials
Quinolone antibacterials were kindly provided by the manufacturers: moxifloxacin, ciprofloxacin, and Bay Y3118 (Bayer, Wuppertal, Germany); sparfloxacin and pefloxacin (Rhône-Poulenc-Rorer, Vitry sur Seine, France); clinafloxacin (Parke-Davis, Ann Arbor, MI, USA); norfloxacin (Merck, Rahway, NJ, USA); grepafloxacin (Glaxo, Stevenage, UK); levofloxacin (Hoechst, Frankfurt, Germany); trovafloxacin (Mack Microbiology Division of Pfizer, Illertissen, Germany).
Bacterial strains
Bacterial strains and their relevant genetic markers are given in Table I . E. coli strains WT and 205096 have been described previously. 10 E. coli strains MI, MII, MIII, MIVa, MIVb, and WT3-M4 were selected in our laboratory.
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Staphylococcal strains were kindly provided by Dr A. Schmalreck, Mack Microbiology Division of Pfizer.
Susceptibility testing
Drug susceptibilities were determined by micro-broth dilution according to the guidelines established by the NCCLS 12 except that Isosensitest-broth (Oxoid) was used instead of Mueller-Hinton broth.
Evaluating the antibacterial activity in vitro
The impact of an individual mutation on the antibacterial activity in vitro was investigated by comparing the differences in the MIC dilution steps for E. coli mutants and the respective isogenic parent. The data obtained for a susceptible strain of S. aureus (ATCC 25923) were compared with a grlA mutant (72000V191), a gyrA, grlA double-mutant (29751) and the high-level resistant strain NMS54 carrying multiple mutations including a mutation affecting quinolone accumulation.
To compare the overall antibacterial activities of the different quinolones against the various mutants and the respective wild-type, a factor of activity (F A ) was calculated as the sum of serial dilution steps by which the MIC of a compound differs from that of the most active one for the respective strain divided by the total number of strains tested. The lowest MIC value is set to 1. Thus, the closer a factor approximates 1 the higher is the antibacterial activity of a compound. 
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a Indicated is the amino acid position and the amino acid exchange in one letter code. Reduced ciprofloxacin accumulation by at least 50%. c Mutation detected by RFLP analysis. 
Mutation frequency
The frequency of drug-resistant spontaneous mutants was determined by spreading c. 10 -11 cfu in ten 50 L aliquots on china-blue-lactose agar (Oxoid, Basingstoke, Hampshire, UK) containing the selecting antimicrobial agent at a concentration of 4 ϫ MIC. The mutation frequency was calculated as the number of resistant colonies per inoculum.
Genetic modification and analysis
Sensitivities to and affinities for quinolones of gyrase and topoisomerase IV containing mutations in the quinolone resistance-determining regions of the respective A subunits were investigated in vivo by susceptibility testing and in vitro with isolated enzymes. The following mutations were introduced into E. coli strain WT 11 to yield mutants WT-4 (parC Ser80ǞIle), WT3-2 (gyrA Asp87ǞGly), and WT-3 (gyrA Ser83ǞLeu and Asp87ǞGly), 13 respectively, by using the gene replacement technique of Hamilton et al.
14 Briefly, DNA fragments carrying mutant alleles of the respective genes were amplified and cloned into the plasmid vector pMAK705, which mediates resistance to chloramphenicol and contains a thermosensitive origin of replication. After transformation, recombinant cells were maintained at 43°C in the presence of chloramphenicol to select for clones carrying the plasmid integrated into the chromosome by homologous recombination. These clones were subsequently grown at permissive temperature (30°C) in the presence of chloramphenicol to allow for the resolution of cointegrates. Fast growing clones were shifted to the restrictive temperature (43°C) and grown in the absence of chloramphenicol. This provides a selective advantage for plasmid-less cells. Those clones which have lost the resolved gene copy and simultaneously have retained the mutated allele in the chromosome were identified by phenotypic (susceptibilities to antibiotics) and genetic markers (DNA sequencing). S. aureus topoisomerase mutations were identified by RFLP-analysis of PCR-fragments. 15 
Ciprofloxacin accumulation
The percentage of ciprofloxacin accumulated by an E. coli strain after 20 min of incubation was determined essentially as described previously. 16 Briefly, cells were grown under aeration at 30°C to mid-log phase (OD 570 ϭ 0.7). Ciprofloxacin was added to a final concentration of 100 mg/L and cells were incubated at 30°C with aeration for 20 min. Ten samples of 1 mL were withdrawn, immediately transferred on top of 0.5 mL of a silicone oil mixture (one part AK100:two parts AR200; Wacker Chemie, Munich, Germany) and centrifuged immediately at 13,000g for 120 s at 4°C. Supernatant was discarded and pellets were dried overnight in the dark. The dried pellets were resuspended in 1 mL 0.1 M glycine hydrochloride (pH 3.0). Samples were centrifuged immediately before measuring, in the supernatant, the emission at 445 nm with an excitation at 276 nm in a Perkin-Elmer 1000 fluorescence spectrophotometer according to Chapman & Georgopapadakou. 17 Valueswere compared with those obtained with a standard curve of 0.02-0.2 ng/mL in 0.1 M glycine hydrochloride (pH 3.0).
Topoisomerase assays
The preparation of crude cell lysates from strains of E. coli overproducing plasmid-coded proteins GyrA, GyrB, ParC, and ParE was performed as described previously. [18] [19] [20] The effect of GyrA mutations on the sensitivity of gyrase to quinolones was examined in a supercoiling inhibition assay: one unit of enzyme was defined as the amount of protein capable of converting 0.5 g pBR322 DNA from the relaxed to the supercoiled state within 30 min at 30°C. 21 The effect of the ParC mutation on the sensitivity to quinolones of topoisomerase IV was examined in a decatenation assay. 22 One unit of enzyme was defined as the amount of protein capable of decatenating 0.3 g kinetoplast DNA (TopoGEN Inc., Colombus, OH, USA) within 30 min at 37°C. Percentage of drug inhibition was calculated by performing a densitometric analysis using the WinCAM 2.2 software (Cybertec, Berlin, Germany). IC 50 values were calculated by linear correlation.
Results
Susceptibility testing
On the basis of F A , Bay Y3118, which is not being developed for clinical use due to intolerable side-effects, was by far the most active compound in vitro against all mutants tested (F A ϭ 1.54 for E. coli, 1.0 for S. aureus), followed by clinafloxacin (F A ϭ 1.81 for E. coli, 2.2 for S. aureus) which is not yet commercially available (Table II) . Thus, these quinolones served as reference compounds. Against S. aureus mutants, moxifloxacin (F A ϭ 2.6) was comparable to trovafloxacin (F A ϭ 2.4) and more active than other currently available quinolones (F A Ͼ 3.2). Against E. coli mutants moxifloxacin (F A ϭ 2.9) is nearly as active as ciprofloxacin and sparfloxacin (F A ϭ 2.81 for both) as well as levofloxacin (F A ϭ 2.45). The results of the MIC determinations are summarized in Table III. For some high-level resistant mutants of E. coli (MIVa, MIVb, 205096) moxifloxacin and levofloxacin had the lowest MIC values (Table III) . For mutants of S. aureus with high-level ciprofloxacin resistance (S. aureus 19400/ U92, 129751, NMS 54) moxifloxacin was more active than currently available fluoroquinolones, except trovafloxacin. The activity of moxifloxacin against the type strains of E. coli (ATCC 35922; MIC 0.03 mg/L) and S. aureus (ATCC 25923; MIC 0.06 mg/L) is equivalent or better than other compounds (excluding Bay Y3118 and clinafloxacin). 
Enzyme inhibition
The impact of gyrA or parC mutations on the affinities of various quinolones for isolated target enzymes of E. coli were determined as IC 50 values and are included in Table  IV . The reference compounds again were the most active quinolones against all six enzyme variants tested, with the exception of ciprofloxacin, which had the lowest IC 50 value (27 mg/L) against wild-type topoisomerase IV. However, an isoleucine-80 mutation in topoisomerase IV results in a considerable increase in the IC 50 value for ciprofloxacin (125 mg/L), similar to values determined for sparfloxacin (64.3 to 105.3 mg/L) and norfloxacin (62.2 to 115.2 mg/L), while moxifloxacin (68.4 to 79.7 mg/L) and clinafloxacin were not affected and Bay Y3118 only marginally affected (Table IV) . Similarly a gyrA double mutation with leucine-83 and glycine-87 resulted in an at least 500-fold increase in the IC 50 values for ciprofloxacin, sparfloxacin and norfloxacin compared with the wild-type enzyme, while the increase in IC 50 values was only twelve-fold for moxifloxacin, or less for the reference compounds. In contrast single gyrA mutations resulted in only small increases (less than two-fold).
Mutation frequency
The mutation frequencies of the single-step mutants E. coli MI (gyrA, Ser83ǞLeu), E. coli WT-4 (parC, Ser80ǞIle) and their isogenic parent E. coli WT, were determined by selecting mutants on agar containing either moxifloxacin, ciprofloxacin, grepafloxacin or trovafloxacin in a concentration of 4 ϫ MICs. The results are summarized in Table  V . While the mutation rates of E. coli WT and its singlestep gyrA mutant MI are within the range of the 'normal' mutation frequency of р10 -8 for all four quinolones tested, resistant mutants of the single-step parC mutant WT-4 were obtained with higher frequencies (5 ϫ 10 -7 to 1.9 ϫ 10 -6 ). The increase in the mutation rate between WT and WT-4 is about 40-fold for ciprofloxacin, about 1300-fold for moxiflocain, 2100-fold for grepafloxain and more than 100,000-fold for trovafloxacin (Table V) .
Discussion
Various parameters have been used to evaluate the antibacterial activity of various fluoroquinolones. These include the susceptibility of whole cells (MIC), the activity on isolated target enzymes (IC 50 ) and the ability to select resistant mutants (mutation frequency).
Assuming a breakpoint of Ͼ1 mg/L for clinical resistance, single-step mutations affecting gyrase in E. coli (strains MI, WT-3.2) are unlikely to be of clinical relevance for moxifloxacin. On the other hand, the MICs of most quinolones increase by three to four dilution steps, except for ciprofloxacin and sparfloxacin (five dilution steps) and norfloxacin (two dilution steps). In contrast, a parC mutation (WT-4) had none or only a marginal impact on the MIC of all quinolones tested (one dilution step).
Introducing a second gyrA mutation into a gyrA mutant such as MI, WT-3.2 to produce strain WT-3 does not increase the MIC by more than two dilution steps. In contrast, a combination of one parC and two gyrA mutations (strains MIII, MIVa, MIVb, 205096 and WT-3-M4) results in clinical resistance to all fluoroquinolones tested with an MIC increase of three to six dilution steps. The preferential targeting of E. coli DNA gyrase in favour of topoisomerase IV by fluoroquinolones is expressed by IC 50 values determined for gyrase that are one order of magnitude lower than those for topoisomerase IV. GyrA and parC mutations in E. coli type II topoisomerases led to a significant decrease in the inhibitory activities of all fluoroquinolones against the isolated enzymes. These data support the current view that gyrase is the susceptible, primary target of quinolones in E. coli.
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The results for S. aureus strains containing different mutations are less comparable since the strains are not clonally related. Nevertheless, a single grlA mutation in strain 72000V191 resulted in an increase of MIC by one to three dilution steps for the different quinolones. However, owing to the lower intrinsic activity of ciprofloxacin, pefloxacin and norfloxacin, the MIC values are at or above the breakpoint. In combination with gyrA mutation(s), the MICs of most quinolones increased by at least four dilution steps compared with the type strain. These data for S. aureus isolates are in agreement with data from Ferrero et al. 6, 7 showing that the primary target for ciprofloxacin in S. aureus is topoisomerase IV.
The correlation (r ϭ 0.918) found between the MICs of these fluoroquinolones for E. coli WT-3-M4 and the IC 50 values for mutant topoisomerase IV (Ser80ǞIle) ( Figure  2 ) demonstrates the significance of the enzyme inhibition for the bactericidal effects of the quinolones under the given experimental conditions. In addition, it provides evidence that in the genetic background of a gyrA double mutation (WT-3-M4) the parC Ser80ǞIle mutation is the determinant for the quinolone susceptibility. This is in contrast to the IC 50 data obtained for mutant topoisomerase IV (Ser80ǞIle) and double-mutant gyrase (Ser83ǞLeu ϩ Asp87ǞGly), respectively, which are not comparable. Thus, there is a general discrepancy between quinolone inhibitory concentrations obtained from MIC determinations and enzyme assays. This is probably due to the different biological effects: for inhibition of cell growth only a small fraction of active enzyme needs to be inhibited, 8 while inhibition of the enzyme activity requires more than 90% of the enzyme to be inactivated. The development of high-level fluoroquinolone resistance in bacteria is explained by the accumulation of multiple mutations in enzyme targets. 23 The rapid increase in quinolone resistance among Gram-negative and Grampositive pathogens during the past five years in central Europe 24 suggest that new fluoroquinolones should have high activity against both targets, DNA gyrase and topoisomerase IV. Apart from Bay Y3118 and clinafloxacin which served as reference compounds, moxifloxacin was the only fluoroquinolone tested that had such equivalent high activity against both topoisomerase targets. ence on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA, 1998 (H. Schedletzky, B. Wiedemann & P. Heisig, Abstract E202). Part of this work was supported by a grant from the Deutsche Forschungsgemeinschaft (He1864/1-3) to P.H.
